Testing a heart medication for a rare protein disease

Plain-English translation of NCT06318260 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a medication called Dobutamine in patients with a rare heart disease caused by abnormal protein buildup (wild-type transthyretin amyloid cardiomyopathy). The study wants to see if this medication can help the heart pump more effectively and reduce pressure buildup in the lungs, while also checking that the medication is safe to use in people with this condition.

People with this rare protein disease often have hearts that don't pump well, leading to shortness of breath and fatigue. Doctors need to know whether this medication can help improve heart function and reduce symptoms in these patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with wild-type transthyretin amyloid cardiomyopathy (confirmed by genetic testing or biopsy)
you are 65 years of age or older
you are currently taking water pills (loop diuretics) for your heart
your heart's pumping ability is reduced (ejection fraction below 50% or stroke volume index below 35)
you experience shortness of breath with light activity or at rest (New York Heart Association class II-IV)

You likely don't qualify if…

you have a severe aortic valve problem or other significant valve disease
you have severe blockages in multiple heart arteries or a recent heart attack (within 4 weeks)
you are allergic to dobutamine or sulfites
you have a condition called phaeochromocytoma or a history of dangerous heart rhythm problems
you have severe kidney disease (kidney function below 15 mL/min/1.73 m²)

What participation looks like

You will come to the hospital for one day of testing. First, you'll have your blood pressure, heart rate, and an ECG recorded, along with an ultrasound of your heart. Then, doctors will insert a thin catheter tube into a vein in your neck to measure the pressures inside your heart while the medication is slowly given through an IV, and this will be monitored with another ultrasound at the same time. The entire visit involves non-invasive heart imaging and one invasive procedure to measure how your heart responds to the medication.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(1 site)

Denmark

Department of Cardiology, Aarhus University Hospital, Aarhus